



## AtriCure to Announce Third Quarter 2025 Financial Results

October 8, 2025

MASON, Ohio--(BUSINESS WIRE)--Oct. 8, 2025-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, October 29, 2025.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, October 29, 2025, to discuss its third quarter 2025 financial results. Those interested in listening to the conference call should [register online using this link](#). Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at <https://ir.atricure.com/events-and-presentations/events>.

### About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator<sup>®</sup> Synergy<sup>™</sup> Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip<sup>®</sup> Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF<sup>™</sup> Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE<sup>®</sup> and cryoXT<sup>®</sup> probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit [AtriCure.com](https://www.atricure.com) or follow us on X @AtriCure.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251008040070/en/): <https://www.businesswire.com/news/home/20251008040070/en/>

Angie Wirick  
AtriCure, Inc.  
Chief Financial Officer  
(513) 755-5334  
[awirick@atricure.com](mailto:awirick@atricure.com)

Marissa Bych  
Gilmartin Group  
Investor Relations  
[marissa@gilmartinir.com](mailto:marissa@gilmartinir.com)

Source: AtriCure, Inc.